Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready
Clara Foods Co. manages a portfolio in the Biotechnology & Pharmaceuticals technology area with 7 pending office actions. These actions are distributed among 6 distinct examiners, showing a high level of individual attention for each filing. The prosecution activity is spread across 5 distinct art units, indicating a variety of technical applications within the biotechnology sector.
MORNHINWEG, JEFFREY P is the busiest examiner for the company, currently handling 2 busiest examiner pending actions. This leaves the other pending office actions to be managed by the remaining 6 distinct examiners. Such a distribution suggests that the company's legal strategy is not overly dependent on the tendencies of a single examiner.
With 7 pending office actions, the portfolio demonstrates significant breadth. The ratio of distinct examiners to actions ensures that most cases are evaluated independently. This variety in both examiners and 5 distinct art units provides a broad foundation for the company's intellectual property efforts in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MORNHINWEG, JEFFREY P | 2 | 36.3% | +32.1% |
| TSAY, MARSHA M | 1 | 45.7% | +52.7% |
| MOEHLMAN, ANDREW TERRY | 1 | 66.3% | +61.0% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| LYONS, MARY M | 1 | 65.5% | +41.5% |
| BEKKER, KELLY JO | 1 | 16.7% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18296654 | PROTEIN COMPOSITIONS AND CONSUMABLE PRODUCTS THEREOF | BEKKER, KELLY JO | 9d |
| 18344790 | SURFACE DISPLAYED FUSION PROTEINS | OGUNBIYI, OLUWATOSIN A | 22d |
| 18344773 | PROTEIN COMPOSITIONS AND METHODS OF PRODUCTION | LYONS, MARY M | 22d |
| 18614533 | BEVERAGE CLARIFICATION USING RECOMBINANT OVA OR OVD | MORNHINWEG, JEFFREY P | 61d |
| 18751204 | PROTEIN COMPOSITIONS AND CONSUMABLE PRODUCTS THEREOF | MORNHINWEG, JEFFREY P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18296654 | PROTEIN COMPOSITIONS AND CONSUMABLE PRODUCTS THEREOF | BEKKER, KELLY JO | 9d |
| 18344790 | SURFACE DISPLAYED FUSION PROTEINS | OGUNBIYI, OLUWATOSIN A | 22d |
| 18344773 | PROTEIN COMPOSITIONS AND METHODS OF PRODUCTION | LYONS, MARY M | 22d |
| 19264681 | PURIFIED PROTEIN COMPOSITIONS AND METHODS OF PRODUCTION | TSAY, MARSHA M | 33d |
| 18614533 | BEVERAGE CLARIFICATION USING RECOMBINANT OVA OR OVD | MORNHINWEG, JEFFREY P | 61d |
| 18751204 | PROTEIN COMPOSITIONS AND CONSUMABLE PRODUCTS THEREOF | MORNHINWEG, JEFFREY P | — |
| 18346095 | SURFACE DISPLAYED ENDOGLYCOSIDASES | MOEHLMAN, ANDREW TERRY | — |
| Art Unit | Apps |
|---|---|
| 1793 | 2 |
| 1645 | 2 |
| 1656 | 1 |
| 1655 | 1 |
| 1792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19264681 | PURIFIED PROTEIN COMPOSITIONS AND METHODS OF PRODUCTION | TSAY, MARSHA M | 1656 | §103§112DP | Non-Final OA | 33d | Pending | Jul 09, 2025 |
| 18751204 | PROTEIN COMPOSITIONS AND CONSUMABLE PRODUCTS THEREOF | MORNHINWEG, JEFFREY P | 1793 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2024 |
| 18614533 | BEVERAGE CLARIFICATION USING RECOMBINANT OVA OR OVD | MORNHINWEG, JEFFREY P | 1793 | §103§112 | Non-Final OA | 61d | Pending | Mar 22, 2024 |
| 18346095 | SURFACE DISPLAYED ENDOGLYCOSIDASES | MOEHLMAN, ANDREW TERRY | 1655 | §102§103§112DP | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18344790 | SURFACE DISPLAYED FUSION PROTEINS | OGUNBIYI, OLUWATOSIN A | 1645 | §103§112Other | Non-Final OA | 22d | Pending | Jun 29, 2023 |
| 18344773 | PROTEIN COMPOSITIONS AND METHODS OF PRODUCTION | LYONS, MARY M | 1645 | §102§112 | Non-Final OA | 22d | Pending | Jun 29, 2023 |
| 18296654 | PROTEIN COMPOSITIONS AND CONSUMABLE PRODUCTS THEREOF | BEKKER, KELLY JO | 1792 | §102§103§112Other | Non-Final OA | 9d | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial